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Abstract: Gastrointestinal infection with Shiga toxin-producing Escherichia coli (STEC) causes diarrhea,
hemorrhagic colitis, and hemolytic uremic syndrome (HUS), characterized by hemolytic anemia,
thrombocytopenia and acute renal failure. The main virulence factor of STEC is Shiga toxin (Stx),
which is responsible for HUS development. STEC can produce Stx type 1 and/or 2 (Stx1, Stx2)
and their variants, Stx2 being more frequently associated with severe cases of HUS. This pathology
occurs in 5–15% of cases with STEC infection when Stx gain access to the bloodstream and causes
damage in the target organs such as the kidney and brain. STEC infections affect mainly young
children, although the large HUS outbreak with a new Stx2-producing STEC O104:H4 in Europe in
2011 involved more adults than children, and women were over-represented. Maternal infections
during pregnancy are associated with adverse pregnancy outcomes. Studies in rats showed that Stx2
binds to the utero-placental unit and causes adverse pregnancy outcomes. In this article, we provide
a brief overview of Stx2 action on placental tissues and discuss whether they might cause pregnancy
loss or preterm birth.
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1. Introduction
Shiga toxin-producing Escherichia coli (STEC) cause a significant public health risk due to
contamination of food and water supplies. STEC produces gastrointestinal infections that may produce
diarrhea and hemorrhagic colitis, and is the principal cause of hemolytic uremic syndrome (HUS),
a systemic complication that is attributed to the action of Shiga toxins (Stx) [1]. STEC can produce
two antigenically diverse forms of Stx proteins (Stx1 and Stx2) and their variants, Stx2 being more
virulent and epidemiologically more relevant than Stx1 [2]. Once ingested, STEC colonizes the human
intestine, releasing Stx which crosses the epithelial barrier and reaches the target organs by the
systemic circulation. It is well known that Stx binds Gb3 receptors on the endothelial cells, goes
through receptor-mediated internalization followed by retrograde transport to the Golgi apparatus,
and finally induces cell death by inhibition of protein synthesis and consequent cellular apoptosis [3].
HUS is characterized by thrombocytopenia, hemolytic anemia and acute renal failure.
In Argentina, HUS is recognized as the most common cause of acute renal failure in children and
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the second leading cause of chronic renal failure [4,5]. In Argentina, HUS is endemic and has the
highest rate of pediatric cases globally over the last 10 years, with approximately 400 HUS cases
reported annually. This results in an incidence of 10–17 cases per 100,000 children less than 5 years
of age, and lethality of 1 and 4% [6]. Although multiple serotypes of STEC have been isolated from
hemorrhagic colitis cases, E. coli O157:H7 is the most prevalent serotype associated with HUS in
children. However, the large HUS outbreak in 2011 in central Europe caused by a novel Stx2-producing
STEC, affected more adults than children and women were over-represented [7], likely due to children
not being eager consumers of fenugreek sprouts.
During pregnancy the maternal immune response drives physiological adaptations to tolerate the
foreign fetus. However, many pathophysiological situations can interrupt the normal progression of
pregnancy, including genetic and endocrinologic anomalies such as defects on invasion of trophoblast
leading to alterations in the blood irrigation. Nevertheless, many etiologies of obstetric complication
and pregnancy loss are unknown or poorly understood. Infections during pregnancy have been
associated with higher incidence of spontaneous abortion, preterm birth or placental dysfunction [8,9].
However, to our knowledge, an increased risk of spontaneous abortion or preterm delivery in humans
linked to STEC infection has not yet been evaluated.
2. Foodborne Bacteria and Adverse Pregnancy Outcome
It is estimated that infections are responsible for 10–25% of fetal deaths in developed countries,
with bacterial infections more frequently associated with adverse outcomes during early gestation
compared with late gestation [10]. Bacterial infections are especially feared because they may endanger
not only the mother but also her child. Some infections take a more severe course during pregnancy,
probably driven by the physiological and immune alterations in this period that induce an increased
susceptibility to certain pathogens, including viruses, parasites and bacteria. Although immunologic
changes during pregnancy may provide different conditions for entrance of certain infections, pregnant
women are not considered to be immune-suppressed in the classic sense [11]. However, changes
occurring at the feto-maternal interface in order to tolerate the fetal alloantigen may predispose
pregnant women to infections [12]. Taking this into account, pregnant women are considered an
at-risk group for infection caused by foodborne pathogens and often suffer more sequelae as a result
of infection [13,14].
Foodborne disease is defined as any illness related to food ingestion or caused by an infectious
agent carried by food. In some cases of foodborne infection, a pregnant woman may not feel sick but
may still pass the illness to the fetus [15]. For instance, untreated infections may cause stillbirth, preterm
labor or miscarriage by mechanisms including direct fetal infection, placental damage, and severe
maternal illness. The fetal period is of great plasticity, and factors like maternal nutrition, hormones,
and microbial insults can produce epigenetic changes (DNA methylations, for example) that may
modify gene expression in the child, resulting in predisposition to impaired health in adulthood [16–18].
Generally, foodborne pathogens and their virulence factors are transmitted by the hematogenous route,
indeed, systemic infection of the mother may result in the following events: septic abortion, sepsis
causing premature birth or fetal death. The general mechanisms proposed for bacteria gaining access
to the feto-maternal unit are: (a) hematogenous dissemination (transplacental infection), (b) ascension
from the vagina and cervix, (c) accidental introduction at the time of invasive procedures such as
amniocentesis, (d) chorionic villous (placental tissue) sampling or shunting for prenatal genetic
diagnosis, (e) retrograde from the peritoneal cavity through the fallopian tubes, and (f) contaminated
food or mouth infections [19,20]. Another essential point is that mother to child transmission of
infection can occur not only during pregnancy (vertical transmission), but also during labour or in the
postpartum period.
The effects of several human foodborne bacteria have been recognized for many years. Indeed,
Listeria monocytogenes, Coxiella burnetii, Campylobacter jejuni, Salmonella typhi, and E. coli are well
known foodborne bacterial pathogens that may produce adverse outcomes during pregnancy [21,22].
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Listeria monocytogens is the most studied pathogen particularly affecting pregnancy, and it is responsible
for long term consequences, mainly for the baby. Infection is transmitted by animals or animal products,
usually milk and dairy products [23]. Thus, listeriosis is considered a zoonosis and has been implicated
in stillbirth, preterm labor, newborn sepsis, and meningitis, among other complications [14]. Even if the
effects of some infectious bacterial agents are well known, currently there is still a lack of knowledge
about emerging pathogens [12]. For instance, E. coli are commensal bacteria of the intestine of humans
and animals but some pathogenic strains can cause moderate to severe gastrointestinal disease in
humans. STEC is an emergent pathogen associated with foodborne diseases, although the risk of
spontaneous abortion or preterm delivery in humans associated with STEC infection has not yet
been evaluated.
Infections may cause early pregnancy loss (which occurs before 12 weeks of pregnancy),
late pregnancy loss (which occurs between 12–20 weeks of gestation), or fetal death (which occurs
during the third trimester) [24]. Giakoumelou et al. [25] performed a retrospective study of clinical cases
to evaluate the role of infections during pregnancy. These authors concluded that there is evidence
of infectious agents that affect pregnancy, as those cited before, and dismissed others including
Mycoplasma genitalium and Chlamydia Trachomatis, for example. On the other hand, these authors
confirmed the real ignorance about infectious agents that affect pregnancy and in which, physiological
mechanisms are induced by infectious agents in fetal tissues [25].
3. Pathophysiology of Adverse Pregnancy Outcomes Caused by Infections
Feto-maternal interface is comprised of placental and fetal membranes (amnion and chorion).
The feto-maternal interface may be divided into the fetal and the maternal side. In amongst the fetal side
of the interface, the placenta and membranes, are allograft tissues. In this sense, fetal allograft contact
the maternal blood through the syncytiotrophoblast, a specialized epithelial cell of the placenta that
acts as an important component of the feto-maternal barrier. On the other hand, decidua is maternal
remodeled uterine tissue in contact with the placenta and fetal membranes, where specialized immune
cells such as macrophages and lymphocytes reside. A delicate and still not well-known mechanism
in the feto-maternal interface occurs to allow tolerance of the allograft fetus during the pregnancy
period. Once a microorganism makes contact with the host, there are several possible pathways that
may be initiated, that may either individually or collectively promote adverse pregnancy outcomes.
Bacteria or endotoxins such as lipopolysaccharide (LPS) are recognized by the innate immune system
through receptors that recognize molecular patterns associated with pathogens. Toll-like receptors
(TLRs) are signaling receptors that activate gene expression programs including the production of
proinflammatory cytokines and type I interferons (INF). The TLR family includes TLR2 that mediates
cellular responses to Gram positive organisms via glycolipids, peptidoglycans and lipoproteins. TLR4
is involved in activation of the innate immune system to exogenous ligands including LPS, which is
abundant on the surface of pathogenic E. coli. When LPS binds its receptor, the nuclear factor of kappa
B (NF-κB) becomes derepressed, and as a consequence, proinflammatory cytokines are expressed [26].
Host inflammatory signaling promotes the recruitment and activation of a variety of host
immune cells. Resident phagocytes (neutrophils, macrophages), circulating inflammatory cells,
antigen-presenting cells, and lymphocytes, in coordination have the function of identifying, antigen
processing, and neutralizing invading pathogens. In addition, an effective innate immune response
allows the proper recruitment and activation of specific immune cells necessary for a strong antibody
response in order to promote the clearance of pathogens and/or to reduce the severity of illness upon
reinfection [27]. However, innate immune cells such as neutrophils, may induce fatal disease in the
mother and/or fetus instead to provide protection.
While inflammation of the uterine environment is essential for processes like implantation and
placentation, its exacerbation may lead to complications such as premature delivery and pre-eclampsia.
There is much evidence that inflammation in fetal tissues may impair long or short-term normal
pregnancy. Histological infiltration of the tissue by neutrophils, macrophages and lymphocytes defines
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if inflammation is acute or chronic. There is a window of time between the cellular infiltrate and the
molecular signals (induction of proinflammatory cytokines or adhesion molecules) that mediate this
migration. It is often the case that this type of histological inflammation is ruled out when the systemic
clinical symptoms such as inflammation, reddening, heat, pain and tumor are not found. Clinical
evidence shows that most histological inflammations, including inflammation of chorioamniotic
membranes, are subclinical [28].
4. STEC Infection May Be Responsible for Pregnancy Complications
To our knowledge, there are no reports of Stx effects during human pregnancy or described
pregnancy complications associated with STEC infection. There are some reported cases of neonatal
HUS caused by STEC transmission from mother to the newborn during delivery [29,30]. Also a few
cases of STEC-mediated HUS during pregnancy have been reported [31–33].
Several studies in animal models have demonstrated that Stx2 causes spontaneous abortion and
perinatal complications. It is possible that the effects observed may be a consequence of a direct action
of Stx on the placental tissues. Even if most of the reported studies regarding Stx and pregnancy were
referred to Stx2, we cannot exclude that similar events may be triggered by Stx1. With respect to this,
both Stx1 and Stx2 have been reported to induce apoptosis in WISH cell line derived from human
amniotic tissue [34] and Stx2 impairs migration and invasion in the cell line Swan71 used as a model
of human trophoblasts [35].
Some authors have shown that Stx affects pregnancy in rodents. Burdet et al. [36] reported
that a combination of Stx2 and LPS intraperitoneally injected in rats in the late stage of pregnancy
produces preterm delivery of dead fetuses. An overproduction of nitric oxide (NO) and damage in the
placenta prevented by aminoguanidine (AG), an inducible NO synthase inhibitor, demonstrated that
NO plays an important role in placental toxicity and fetal mortality induced by Stx2 [37]. In addition,
NO overproduction induces embryonic resorption in mice [38,39]. Moreover, NO may stimulate the
activity of cyclooxygenase and cause an increase in prostaglandins (PGs) synthesis. In this sense,
it has been reported that PGs, produced by uterine tissues in the surroundings of infection, cause
cervical dilatation and uterine contractions leading to a premature delivery [40]. The production
of PGs and expression of COX-2 protein were modulated by the NOS activity in Stx2-treated rats.
Additionally, Stx2 may induce the production of tumor necrosis factor alpha (TNF-α) that renders
the feto-maternal unit more susceptible to Stx2 through the stimulation of local PGs synthesis [41].
Many studies conducted in human and experimental animals determined that a correct balance of
cytokines at the maternal-fetal interface is an essential requirement for correct placental development,
and therefore, reproductive success [42,43]. Burdet et al. [41] reported that the combined action of AG
and Etanercept, a recombinant human tumor necrosis factor receptor fusion protein that binds TNF-α,
prevented preterm delivery. This data indicates that TNF-α may play a causal role in pregnancy loss
consistent with previous studies of preterm delivery reported in humans [44].
Stx2 can also cause spontaneous abortion in mice by damaging trophoblasts and producing
intrauterine hemorrhage, fibrin deposition, and neutrophil infiltration [45]. Abortion has been also
demonstrated in rats, since morphological and histological damage in the uteroplacental unit as well
as feto-maternal resorptions have been reported after sublethal dose of Stx2 in the early stage of
pregnancy [46]. Stx2 binds to the microvasculature and decidual cells where a significant hypoxia and
intrauterine growth restriction (IUGR) have been detected [47]. The detrimental effect of Stx2 was
also enhanced by a local inflammation state rendering the cells more sensitive to the toxin as occurs in
other target organs [48].
Both inflammation and hypoxia are adaptive mechanisms by which organisms respond to the
disturbance of the function of an organ. Both mechanisms play an important role in pathological
processes such as IUGR, spontaneous abortion, preeclampsia and preterm delivery [49]. Although,
initially the uterine physiological environment for trophoblastic invasion is characterized as being
hypoxic, it becomes highly oxygenated when the remodeling of the uterine spiral arteries is completed.
Microorganisms 2018, 6, 111 5 of 10
Hypoxia is essential in normal fetal development for both vasculogenesis/angiogenesis, hematopoiesis,
chondrogenesis and for feto-placental development in general [50]. However, excess of hypoxia leads
to abnormalities in the development. Complications due to fetal hypoxia are one of the most important
causes of fetal death [51]. It is known that hypoxia generates Reactive Oxygen Species (ROS) that can
subsequently regulate the transcriptional and post-transcriptional response of hypoxia-responsive
genes [52]. Therefore, the inhibition of ROS in hypoxic conditions inhibits some of the transcriptional
responses triggered during this condition. Hypoxic conditions can also lead to a proinflammatory
state [53]. Oxygen partial pressure regulates the inducible factor by hypoxia-1 (HIF-1). HIF-1 is
composed of two subunits, HIF-1α sensitive to oxygen and HIF-1β constitutively expressed. HIF-1α
is a labile protein against oxygen that stabilizes under hypoxic conditions [50]. This process is finely
regulated by prolyl hydroxylases that hydroxylate HIF-1α under normoxic conditions and lead
to its degradation by interaction with the tumor suppressor protein von-Hipple Lindau (p-VHL).
Under conditions of hypoxia, HIF-α is not hydroxylated, does not bind to p-VHL and is translocated
to the nucleus, activating the transcription of genes known as hypoxia response: vascular endothelial
growth factor (VEGF), erythropoietin, transferrin, rust inducible nitric acid synthase, endothelin-1,
among others [54]. Included within the genes regulated by HIF are those genes that regulate the
process of angiogenesis, such as VEGF among others [55]. VEGF was described in rat placental tissues
to be downregulated by Stx2 and we can speculate that inhibition of protein synthesis by the toxin
may also alter HIF expression [47].
As previously was mentioned, several physiological changes occur in the mother during
pregnancy, within which adequate cardiovascular adaptation (increased cardiac output) to provide
uterine perfusion is necessary to meet fetal needs. The placenta needs adequate remodeling of the
uterine arteries and vascularization to ensure the transport of nutrients and oxygen to the fetus.
An impairment in the development of the placental vessels leads to fetal deterioration. The reduction
in fetal blood flow may be due to a reduction in utero-placental blood flow or an abnormal villous
structure at the feto-maternal-placental interface [56]. Moreover, the placental inflammatory state
produces accumulation of immune cells that can lead to hypoxia by oxygen consumption of these cells
added to the decrease in blood perfusion at the fetus-maternal-placental interface [57].
In this sense, symptomatic or asymptomatic STEC infections during early pregnancy may cause
maternal or fetal damage mediated by Stx2. In consequence, STEC infection during pregnancy may
cause maternal or fetal damage mediated by Stx2. These data support the hypothesis that similar
events may occur during human pregnancy (Figure 1).
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5. Strategies to Prevent STEC Infection During Pregnancy
Due to the high incidence of HUS in Argentina and the lack of a licensed vaccine or specific and
effective therapy, primary prevention is fundamental to decrease the impact of HUS. One important
challenge is to develop an effective, safe and nontoxic immunogen, also able to induce long-lasting,
high-affinity antibodies that assure good neutralization capacity in serum. Epidemiological studies
that refer to the prevalence of antibodies in children and in the adult population, showed that after
the second decade of life, the anti-Stx antibody titers increases and then declines in the elderly [58].
These results agree with the incidence of HUS that mainly affects children. The study of two outbreaks
of STEC infection associated the seropositivity of anti-Stx antibodies with protection to the development
of symptoms associated with STEC, while the individuals seronegative for Stx had symptoms [59].
Prevalence studies of anti-Stx antibodies in Argentina show that 67% of healthy children have anti-Stx2
antibodies and 8% anti-Stx1 antibodies, while 86% of children with HUS had anti-Stx2 antibodies.
In turn, it was also shown that there is more persistence of antibodies against the A subunit than the B
subunit of Stx2 [60]. Consistent with these findings, a previous study reported anti-Stx2 seroreactivity
in adults, generally refractory to HUS [61].
To date, there is still no specific treatment for HUS patients, leaving only the clinical management
of support as an alternative. The prevention of infections by STEC and the development of HUS at
the consumer level, lies in proper cooking of food, avoiding cross contamination (do not cut raw
vegetables on the same table or with the same knife that cuts raw meat) and consuming pasteurized
dairy products, to mention the most usual measures [62].
Epidemiological studies on the prevalence of anti-Stx antibodies in the population, reveals the
importance of anti-Stx antibodies as a therapeutic strategy to prevent HUS. In the development of this
strategy, several tests were carried out with anti-Stx monoclonal antibodies that have shown to be an
effective therapeutic tool to protect cells and organs from the action of Stx2 in vitro and in vivo [63,64].
Additionally, a specific antibody against E. coli O157 LPS has been described in serum [33] as well
as in breast milk of pregnant women with HUS [65], which may be advantageous for protecting the
newborn against STEC infection. In animal models, it was demonstrated that maternal immunization
against Stx2, protects dams from Stx2 mediated pregnancy loss. Additionally, immunized dams confer
to the offspring, through lactation, protection against a lethal dose of Stx2 [66–68]. In this regard,
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maternal immunity against Stx may be important to protect pregnancy and the breastfeeding neonate
(Figure 1). Recent advances that link maternal STEC infections with abortion and preterm labor suggest
the importance of controlling STEC infections in pregnant women.
Further epidemiological studies about the prevalence of symptomatic or asymptomatic STEC
infections in pregnant women and the correlation with adverse pregnancy outcomes will help
to understand the role of STEC infections during pregnancy. Additionally, it will be relevant to
demonstrate if anti-Stx antibodies in human milk have the ability to neutralize STEC infections in
neonates in order to protect against HUS.
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